Next Article in Journal
Paeoniflorin Enhances Endometrial Receptivity through Leukemia Inhibitory Factor
Next Article in Special Issue
Partial Decellularization for Segmental Tracheal Scaffold Tissue Engineering: A Preliminary Study in Rabbits
Previous Article in Journal
Role of Oxidative Stress in the Pathogenesis of Amyotrophic Lateral Sclerosis: Antioxidant Metalloenzymes and Therapeutic Strategies
Previous Article in Special Issue
Development of Standardized Fetal Progenitor Cell Therapy for Cartilage Regenerative Medicine: Industrial Transposition and Preliminary Safety in Xenogeneic Transplantation
 
 
Article

The Effect of Alendronate on Osteoclastogenesis in Different Combinations of M-CSF and RANKL Growth Factors

1
Department of Tissue Engineering, Institute of Experimental Medicine, The Czech Academy of Sciences, Videnska 1083, 142 20 Prague, Czech Republic
2
Department of Chemistry, Faculty of Science, Humanities and Education, Technical University of Liberec, Studentska 1402/2, 461 17 Liberec, Czech Republic
3
InoCure, Politických Vězňů 935/13, 110 00 Praha, Czech Republic
*
Author to whom correspondence should be addressed.
Academic Editors: Mary C. Farach-Carson and Shanmugam Muruganandan
Biomolecules 2021, 11(3), 438; https://doi.org/10.3390/biom11030438
Received: 14 January 2021 / Revised: 9 March 2021 / Accepted: 11 March 2021 / Published: 16 March 2021
Bisphosphonates (BPs) are compounds resembling the pyrophosphate structure. BPs bind the mineral component of bones. During the bone resorption by osteoclasts, nitrogen-containing BPs are released and internalized, causing an inhibition of the mevalonate pathway. As a consequence, osteoclasts are unable to execute their function. Alendronate (ALN) is a bisphosphonate used to treat osteoporosis. Its administration could be associated with adverse effects. The purpose of this study is to evaluate four different ALN concentrations, ranging from 10−6 to 10−10 M, in the presence of different combinations of M-CSF and RANKL, to find out the effect of low ALN concentrations on osteoclastogenesis using rat and human peripheral blood mononuclear cells. The cytotoxic effect of ALN was evaluated based on metabolic activity and DNA concentration measurement. The alteration in osteoclastogenesis was assessed by the activity of carbonic anhydrase II (CA II), tartrate-resistant acid phosphatase staining, and actin ring formation. The ALN concentration of 10−6 M was cytotoxic. Low ALN concentrations of 10−8 and 10−10 M promoted proliferation, osteoclast-like cell formation, and CA II activity. The results indicated the induction of osteoclastogenesis with low ALN concentrations. However, when high doses of ALN were administered, their cytotoxic effect was demonstrated. View Full-Text
Keywords: alendronate; M-CSF; osteoclastogenesis; RANKL alendronate; M-CSF; osteoclastogenesis; RANKL
Show Figures

Figure 1

MDPI and ACS Style

Hedvičáková, V.; Žižková, R.; Buzgo, M.; Rampichová, M.; Filová, E. The Effect of Alendronate on Osteoclastogenesis in Different Combinations of M-CSF and RANKL Growth Factors. Biomolecules 2021, 11, 438. https://doi.org/10.3390/biom11030438

AMA Style

Hedvičáková V, Žižková R, Buzgo M, Rampichová M, Filová E. The Effect of Alendronate on Osteoclastogenesis in Different Combinations of M-CSF and RANKL Growth Factors. Biomolecules. 2021; 11(3):438. https://doi.org/10.3390/biom11030438

Chicago/Turabian Style

Hedvičáková, Věra, Radmila Žižková, Matěj Buzgo, Michala Rampichová, and Eva Filová. 2021. "The Effect of Alendronate on Osteoclastogenesis in Different Combinations of M-CSF and RANKL Growth Factors" Biomolecules 11, no. 3: 438. https://doi.org/10.3390/biom11030438

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop